Introduction
Hereditary angioedema (HAE) is an autosomal dominant and rare disease which is caused by either a diminished level (HAE type 1) or dysfunction (HAE type 2) of complement C1-inhibitor. [1] [2] [3] Complement C1-inhibitor deficiency causes an uncontrolled activation of the contact system with excessive bradykinin formation as the main outcome. [1] [2] [3] Symptoms of HAE are recurrent angioedema attacks without urticarial signs, typically characterized by swelling of the skin and/or mucosa. Angioedema episodes most frequently affect the extremities, abdomen, head/neck area, and the upper respiratory airways. 1-3 HAE patients do not respond to traditional angioedema treatments, for example, antihistamines, glucocorticoids, and epinephrine, and for many years, HAE patients have been treated off-label with androgens and/or tranexamic acid. Hence, the 2 aagaard and Bygum need for development of more effective and specific HAE treatments has been prevailing for both patients and health care professionals. [4] [5] [6] Traditionally, the pharmaceutical industry did not find it profitable to develop medicines for rare diseases, but with the worldwide implementation of national Orphan Diseases Acts, it has became more economically profitable to develop specific medications for treatment of HAE, the so-called orphan drugs. 7, 8 In the European Union (EU), a rare disease is defined as any disease occurring in less than 5 in 10,000 people, and consequently, orphan drugs are being licensed under favorable conditions with respect to demonstration of efficacy and safety. 8 The EU Orphan Disease Act has led to the development of several new HAE-specific medical treatments, for example, C1-inhibitors, [9] [10] [11] bradykinin receptor antagonists (icatibant), 12, 13 and the recombinant plasma kallikrein inhibitor ecallantide (Kalbitor ® ; Dyax Corp. Burlington, Vermont, USA). [14] [15] [16] Lack of sufficient knowledge of long-term safety aspects from use of orphan drugs in treatment of HAE patients makes spontaneous ADR reporting systems an important source of information about medicine safety. 17 As premarketing clinical trials within the area of rare diseases are scarce, clinicians and health authorities have to rely on spontaneous reports as the major source of new information on ADRs, particularly data on serious and rarely occurring ADRs. 17 Since 2012, researchers have been allowed to access the EU ADR database, EudraVigilance (EV), and this has opened for cross-national analysis based on a standardized reporting format. 18 By February 2016, no studies have systematically analyzed postmarketing safety data reported for orphan drugs licensed for treatment of HAE and submitted to national ADR databases in Europe. 19 The aim of this study was to characterize the adverse events (AEs) reported for orphan drugs licensed for treatment of HAE submitted to the EV database from 2007 to 2013.
Materials and methods study design
We retrospectively reviewed ADR reports submitted to the EV database for orphan drugs licensed for treatment of HAE in Europe. The reported AEs were analyzed with respect to their type and seriousness, age and sex of the patient, suspected medicines, and type of the reporter. The unit of analysis was one ADR. The age groups of the patients were categorized into two: children (0-17 year olds) and adults (18 year olds). AEs reported for HAE medications licensed through the central licensing procedure in the EU by the European Medicines Agency (EMA) were included in this study. The included HAE medications were Berinert ® (CLS Behring, Danderyd, Sweden) Cinryze ® (Shire, Danderyd, Sweden), and Ruconest ® (Shire, Danderyd, Sweden) (C1-inhibitors -ATC code B06AC01) and Firazyr ® (Shire, Danderyd, Sweden) (icatibant) (bradykinin receptor antagonist -ATC code B06AC02). Table 1 displays the characteristics of the included HAE medications, their approved indications and age groups, time of licensing in the EU, name of the marketing authorization holder, and occurrence and type of reported adverse drug reactions listed in the latest version of the official product information. Information about the orphan drugs was retrieved through the website of the EMA. The C1-inhibitor Berinert ® , which is also licensed for acute and prophylactic treatment of HAE, was excluded from this study. Berinert ® is not centrally authorized in the EU, and therefore, we could not get access to the ADR reports reported for Berinert ® through EMA.
Material
The EV database contains information about all suspected spontaneous ADR reports and the ADRs reported in clinical trials and postmarketing for all medicinal products authorized in the EU. 20 ADR data should be transmitted electronically to the database in accordance with the International council on harmonisation of technical requirements for registration of Pharmaceuticals for human use (ICH E2B) (R2) standard. 21 The EV database is not publicly accessible, and authorization for data access was given by the EMA. 22 ADR information was provided for this study in anonymous form with encrypted personal identification. 23 Data extraction and data analyses of the raw material were comprehensive and time consuming. ADR information was extracted from the EV database with respect to the type of reporter and the criteria of seriousness and medications for which the AEs were reported. Criteria of seriousness were evaluated and made by the reporters and the evaluations were confirmed by the national regulatory agencies before forwarding the ADR data to the EV database. The reported AEs were coded according to their type and seriousness using the Council for International Organizations of Medical Sciences criteria by the academic staff in the national regulatory agencies. 24 ADR data were extracted from the EV database in Microsoft Excel files using the following criteria: patient's sex and age, medicines (active substance), adverse drug reaction, and severity. 22 The material comprised all ADR reports submitted to the EV database from 2007 to 2013. Data were extracted from the EV database and delivered to us as several large Excel files. In STATA ® statistical software package (StataCorp LP, College Station, TX, USA), the Excel files were merged into one major file and the ADR reports were searched for duplicates. Data analysis including coding of ADR reports was conducted in an Access database. Each ADR report may refer to one or more suspected ADR(s) as well as to one or more medicinal products. In this study, we only included the AEs reported for medications, which were listed as suspect drug by the reporter, meaning that a causal relationship between the reported ADR and the drug was expected.
Classification of AEs by type and seriousness
The different types of reported AEs were classified according to the Medical Dictionary for Regulatory Activities System Organ Class (SOC). 24 Serious AEs were defined as: fatal, life-threatening, requiring hospitalization or prolongation of existing hospitalization, and resulting in persistent or significant disability/incapacity in the reporter's assessment, in a congenital anomaly/birth defect, and other medically important conditions. All other AEs were classified as nonserious. 24 The scientific staffs working in the different national regulatory agencies made the seriousness evaluations, and these evaluations were forwarded to us together with the copies of the ADR reports.
ethical approval
According to Danish law, no ethical approval was required for this study.
Results
From 2007 to 2013, a total of 79 individual ADR reports containing information about 187 AEs were found in EV for HAE medications licensed by the EMA ( 
aes by seriousness
In total, 60% (n=116) of all reported AEs (n=187) were classified as serious, and among these, three fatal cases were reported ( Table 2) . For Cinryze ® , the share of serious AEs was 57% (n=80) and for Firazyr ® , it was 70% (n=36). The characteristics of the three fatal cases are displayed in Table 3 .
For Cinryze ® , one fatal case of sudden death presumably due to "basilar artery thrombosis" was reported in a 52-year-old male, and one fatal case due to the AEs "cytomegalovirus infection" and "cytomegalovirus test positive" in a male infant was also found in EV for Cinryze ® . For Firazyr ® , one fatal case of sudden death presumably due to "myocardial infarction" was reported in a 67-year-old male.
aes by type and seriousness Table 4 shows the distribution of reported AEs by SOC, seriousness, and medicine. For Cinryze ® , the largest shares of AEs were reported for the SOCs "general disorders and administration site conditions" (25% of the total AEs) and "skin and subcutaneous disorders" (25% of the total AEs). For Cinryze ® , the majority of serious AEs were also found within the SOC "general disorders and administration site conditions" (60% of the reported AEs). For Firazyr ® , majority of the reported AEs were of the type "general disorders and administration site conditions" (49% of the total AEs), and approximately 45% of these AEs were serious. Table 5 displays the number of reported AEs by medicines and seriousness. For Cinryze ® , the largest number of reported AEs was "HAE" (n=25) and "drug ineffective" (n=10); however, only a few of these ADR cases were serious. For Firazyr ® , a large number of nonserious ADR reports on injection site reactions were found in EV. For both Cinryze ® 
aes by medication

Discussion
This is the first study conducted to analyze postmarketing ADR data reported for orphan drugs licensed for treatment of HAE in Europe and submitted to the EV ADR database. Only few ADR reports, all for the medications Cinryze ® and Firazyr ® , were found in EV, and a large number of these were serious. More than one half of AEs were reported for women, and physicians reported all the AEs. A large number of AEs reported for Cinryze ® and Firazyr ® were of the type "general disorders and administration site conditions". The majority of AEs reported for both Cinryze ® and Firazyr ® were not mentioned in the official product information. 17
Reported aes by type and seriousness
The majority of AEs reported for Cinryze ® and Firazyr ® were of the type "general disorders and administration site conditions", for example, injection site reactions, and this ADR pattern was expected due to their route of administration parenteral. Additionally, for Cinryze ® , a large number of AEs of the type "skin and subcutaneous disorders" dia"). Analyses of postmarketing data submitted to the US Food and Drug Administration ADR database showed ten cases of thromboembolic events from use of Cinryze ® . 28, 29 More than one half of the AEs found in EV were serious; however, this reporting pattern was not surprising, since physicians -from a clinical perspective -may find it more relevant to report serious reactions than nonserious reactions. 30 Due to the increasing number of patients diagnosed with HAE, more patients will get access to treatment with orphan drugs, despite the problems with patients' access due to high prices and national restrictions in patients' access, 31 and therefore, a larger number of ADR reports occurring from use of these medications is expected to be reported in the future. [31] [32] [33] Reported aes by therapeutic groups and medications
The largest number of AEs was reported for the medication Cinryze ® , which was expected since Cinryze ® is frequently recommended and used in HAE patients. [4] [5] [6] As expected, no ADR reports were found for Ruconest ® , because this medicine is not prescribed very often for treatment of HAE. For Cinryze ® , a large number of AEs of the type "HAE" were reported, indicating that the medicine may increase the severity of the disease or that the patients/physicians have difficulties in distinguishing between disease symptoms and possible AEs from medication use. The use of orphan drugs in treatment of HAE is considered being low due to the small disease prevalence in EU, the price of the treatments, 28 and limited access to these treatments in some member states. 31 Therefore, we also expected a low number of ADR reports present in EV, and our assumption was confirmed. However, the many serious cases may also indicate that health care professionals and patients report only unknown and serious events, which is also mandatory for the health care professionals operating in the individual EU member states. However, it is also well-known that a high rate of underreporting is biasing the spontaneous reporting systems and probably a much higher number of AEs have occurred in real life. 34 Therefore, we encourage the health care professionals and consumers/patients to continue reporting of suspected AEs in order to increase knowledge about ADRs from use of orphan drugs.
study limitations
The strength of this study is that it comprised all AEs reported for HAE medications in Europe, which were forwarded to the EV database during a 7-year period, hence a limitation were also reported, and these reactions were all listed in the product information. The findings are in line with the ADR patterns reported in another study monitoring the safety of use of C1-inbibitors in different clinical settings in the US and in Europe. 25 Thromboembolic events due to administration of C1-inhibitors have been of concern and discussed in the literature. 26, 27 In this study, only few cases were reported for Cinryze ® ("basilar artery thrombosis" "increased level of coagulation factors IX and VIII", "deep vein thrombosis", "pulmonary embolism", and "tachycar- to this study is that we do not know to which extent the causality of the reported AEs can be confirmed, and this has implications for the interpretation of the findings. The respective pharmaceutical companies make causality assessment of ADR cases as a part of their legal obligations to monitor the safety of their marketed drugs. In this study, we did not evaluate the validity of the ADR reports since we only had access to the data entered into the EV database and not the ADR original reports; however, we expect the data to be valid, as they were predominantly entered into EV by the regulatory agencies. Spontaneous reporting systems suffer from various barriers, such as incomplete recognition of AEs, administrative barriers to reporting, and low data quality, all of which may result in underreporting of important serious and rarely occurring AEs. Hence, AEs that are classified as being nonserious or already known may be underreported; however, this study provides information on the reported AEs, which contributes to broadening the knowledge on medicine safety. Hence, it is not possible to generalize from data reported to the EV database to the other EU member states, as the prescribing practice and disease diagnostic procedures may be very different. Although ADR reporting is mandatory in the EU, it is unknown whether the analyzed ADR data represent all information available in each country, and therefore, the actual ADR prevalence could not be estimated. Spontaneous reports are an important source of information about new and previously unrecognized AEs, and the value of spontaneous reporting schemes lies in their ability to act as hypothesis-generating procedures. 35 Therefore, EMA and the national regulatory agencies should continue to systematically survey and analyze AEs reported by health care professionals/consumers and patients in order to signal previously unknown and rarely occurring AEs presumably related to use of orphan drugs.
Conclusion
Only a few AEs from use of HAE medications were identified in the EV database, but a large majority of these were serious, including fatal cases. There is a need of more research into the prescribing of these medicines to patients with HAE, as well as tighter reporting of AEs for HAE medicines prescribed for this population, particularly from use in children and adolescents.
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